ProMIS Neurosciences Inc. (PMN)
NASDAQ: PMNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
PMN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $28.43M
- EPS (TTM)
- -$6.50
- Dividend yield
- None
- 52-week range
- 2.78 – 27.40
- Day range
- 2.99 – 3.35
- Volume / Avg
- 106.88K / 164.88K
- Beta
- —
- Shares outstanding
- 9.00M
52-week range
PMN stock today
ProMIS Neurosciences (PMN) closed at $3.16 on Nov 20, down 1.56% (-$0.05), versus the S&P 500's 3.70% decline. Shares are 88.5% below their 52-week high of $27.40, set on Mar 5, 2026 and 13.7% above the 52-week low of $2.78, near the bottom of the past year's range. PMN is down 53.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 69.9%.
ProMIS Neurosciences has posted a net loss over the last twelve months (EPS of -$6.50), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About ProMIS Neurosciences
Company profileProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS, which enables drug discovery through a combination of protein biology, physics, and supercomputing.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Neil K. Warma M.B.A.
- Headquarters
- Toronto, ON
- Employees
- 10
- Website
- promisneurosciences.com
Financial highlights
Full financialsProMIS Neurosciences reported a net loss of $39.7 million, compared with net income of $2.8 million a year earlier. Diluted earnings per share came in at -$22.61, down from $2.63.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-39.72M | $2.78M | $-13.21M | $-18.06M | $-9.79M |
| EPS (diluted) | $-22.61 | $2.63 | $-1.07 | $-2.41 | $-1.69 |
Analyst forecast
ForecastConsensus (8 analysts)
none
Avg. price target
$42.61+1248.42%
- Strong buy 2
- Buy 6
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $6.00 vs $-1.26
- Surprise
- +576.19%
PMN news
All PMN news- ProMIS Licenses TXP1 From Ossianix To Deliver Alzheimer's & Parkinson's Therapies To BrainNasdaqPMN, CFR
- ProMIS Neurosciences Licenses Next-Generation TXP1 Brain-Selective Shuttling Technology from Ossianix to Expand PMN310 Franchise and PipelineGlobeNewswire
- ProMIS (PMN) Q3 2026 Earnings Call TranscriptNasdaq
- ProMIS Neurosciences, Inc. Updates Corporate Presentation, Projects Cash Runway Through 2027Nasdaq
- ProMIS Neurosciences to Participate in Upcoming Conferences in NovemberGlobeNewswire
- 4 Biotech Stocks Likely to Outpace Q3 Earnings EstimatesNasdaqTGTX, RGNX, IMNM, PMN
- Can Pharmacy Growth Offset Evernorth's Profit Decline in Cigna's Q3?NasdaqCI, HUM, PAHC, PMN
- Will HCA Healthcare's Q3 Earnings Benefit From Higher Admissions?NasdaqHCA, ILMN, PAHC, PMN
ProMIS Neurosciences peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| AYTUAytu BioPharma Inc. | 2.66 | 0.00% | $28.91M | vs PMN |
| ATHEAlterity Therapeutics Limited ADR | 1.52 | -8.16% | $29.02M | vs PMN |
| RNTXRein Therapeutics Inc. | 0.3369 | -8.38% | $29.06M | vs PMN |
| NNVCNanoViricides Inc. | 1.14 | -2.56% | $29.13M | vs PMN |
| NXTCNextCure Inc. | 6.45 | -4.87% | $29.53M | vs PMN |
| SERSerina Therapeutics Inc. | 1.12 | -6.67% | $29.76M | vs PMN |
| EDSAEdesa Biotech Inc. | 2.00 | -8.05% | $27.02M | vs PMN |
| NSRXNasus Pharma Ltd. | 2.29 | -10.20% | $26.82M | vs PMN |
Indexes, lists and sector
ProMIS Neurosciences stock FAQ
What is ProMIS Neurosciences's stock price today?
PMN last traded at $3.16 as of Nov 20, 4:00 PM EST, down 1.56% on the day. Prices are delayed at least 15 minutes.
Does ProMIS Neurosciences pay a dividend?
No. ProMIS Neurosciences does not currently pay a regular cash dividend.
Who is ProMIS Neurosciences's CEO?
Mr. Neil K. Warma M.B.A. is the chief executive officer of ProMIS Neurosciences Inc., which has about 10 employees.
Has PMN ever split its stock?
Yes. The most recent PMN stock split was a 1-for-25 split on Nov 28, 2025, one of 2 splits on record.
What is the PMN 52-week high?
The 52-week high for PMN is $27.40 and the 52-week low is $2.78. The stock is currently 88.5% below its high.